N-3-fluoropropyl-3-β-(4-iodophenyl)nortropane-2-β-carboxylic acid | 172651-49-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: N-3-fluoropropyl-3-β-(4-iodophenyl)nortropane-2-β-carboxylic acid
• 英文别名: (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-(4-iodophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylic acid
• CAS: 172651-49-9
• 化学式: C₁₇H₂₁FINO₂
• 分子量: 417.262
• InChiKey: BYKIZNNFQUIPSK-JJXSEGSLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-3-fluoropropyl-3-β-(4-iodophenyl)nortropane-2-β-carboxylic acid 在 三氯氧磷 作用下， 生成
  参考文献：
  名称：

  一系列新型的托烷N-或O-氟代烷基衍生物的合成和生物学评估：多巴胺转运蛋白的潜在正电子发射断层扫描（PET）成像剂。

  摘要：

  合成了一系列新颖的含氟烷基的托烷衍生物，并通过竞争性结合试验确定了它们与多巴胺转运蛋白（DAT），5-羟色胺转运蛋白（SERT）和去甲肾上腺素转运蛋白（NET）的结合亲和力。在这些衍生物中，β-CIT的氟丙基酯（19），β-CIT的氟乙基酯（20），β-CBT的N-氟丙基衍生物（12）和β-CMT的氟丙基酯（18）与FP-CIT相比，DAT对SERT和NET具有更高的亲和力和更高的选择性，这表明它们对于DAT的（18）F标记PET显像剂的开发具有吸引力。

  DOI：

  10.1016/s0960-894x(01)00626-6
• 作为产物：
  描述：

  (1R,2S,3S)-8-(3-氟丙基)-3-(4-碘苯基)-8-氮杂双环[3.2.1]辛烷-2-羧酸甲酯 在 水 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-3-fluoropropyl-3-β-(4-iodophenyl)nortropane-2-β-carboxylic acid
  参考文献：
  名称：

  一系列新型的托烷N-或O-氟代烷基衍生物的合成和生物学评估：多巴胺转运蛋白的潜在正电子发射断层扫描（PET）成像剂。

  摘要：

  合成了一系列新颖的含氟烷基的托烷衍生物，并通过竞争性结合试验确定了它们与多巴胺转运蛋白（DAT），5-羟色胺转运蛋白（SERT）和去甲肾上腺素转运蛋白（NET）的结合亲和力。在这些衍生物中，β-CIT的氟丙基酯（19），β-CIT的氟乙基酯（20），β-CBT的N-氟丙基衍生物（12）和β-CMT的氟丙基酯（18）与FP-CIT相比，DAT对SERT和NET具有更高的亲和力和更高的选择性，这表明它们对于DAT的（18）F标记PET显像剂的开发具有吸引力。

  DOI：

  10.1016/s0960-894x(01)00626-6

文献信息

• Medical fluid, a method of treatment and use of the fluid
  申请人：XVIVO PERFUSION AB

  公开号：US10271540B2

  公开（公告）日：2019-04-30

  A medical fluid for a harvested organ, tissue or part thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analog thereof; noradrenaline; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenaline; and noradrenaline are present in concentrations of each about 0.010 μM to 0.100 μM, for example in a ratio of 1:1:1.

  一种用于评估和/或保存摘取的器官、组织或其部分的医用液。该液体包括可卡因或其刺激类似物、去甲肾上腺素和/或肾上腺素。此外，该药液还包括一种抗肿瘤剂，如右旋糖酐；激素，如甲状腺素；三碘酪氨酸；可的松、胰岛素；以及电解质和生理上可接受的介质中基本为生理浓度的营养物质。此外，医用流体还包括浓度不超过 5.0% 的白蛋白和氧载体，如红细胞。其他成分可以是多巴胺、氢化可的松、甲基强的松龙和血管加压剂，如去氨加压素。可卡因、肾上腺素和去甲肾上腺素的浓度各约为 0.010 μM 至 0.100 μM，例如比例为 1:1:1。
• Synthesis of unlabelled, 3H- and 125I-labelled β-CIT and its ϖ-fluoroalkyl analogues β-CIT-FE and β-CIT-FP, including synthesis of precursors
  作者：Carl-Gunnar Swahn、Christer Halldin、Ilonka Günther、Jörg Patt、Simon Ametamey

  DOI：10.1002/(sici)1099-1344(199607)38:7<675::aid-jlcr880>3.0.co;2-l

  日期：1996.7
• A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID
  申请人：XVIVO Perfusion AB

  公开号：EP2568805B1

  公开（公告）日：2019-05-01
• MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID
  申请人：Steen Stig

  公开号：US20130065218A1

  公开（公告）日：2013-03-14

  A medical fluid for a harvested organ, tissue or parts thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analogue thereof; nor-adrenalin; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenalin; and noradrenaline are present in concentrations of each about 0.010 μM to 0.100 μM, for example in a ratio of 1:1:1.
• COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR
  申请人：VIVOLINE MEDICAL AB

  公开号：US20160354359A1

  公开（公告）日：2016-12-08

  A composition, an infusion solution, a method for treatment, and a kit for intravascular administration for treatment of a brain-dead, heart-beating, respirated, potential organ donor. The composition has noradrenaline and a NET inhibitor for noradrenaline. The NET inhibitor may be cocaine or an analogue thereof or a tricyclic antidepressant. The composition may in addition include adrenaline, hydrocortisone, thyroxin, insulin, triiodotyronine, dopamine, a vasopressor agent, such as desmopressin, and methylprednisolone. The ratio between the NET inhibitor and noradrenaline is about 1:1. The composition may be dissolved in pure water, Ringer's acetate solution or physiological sodium chloride solution. The composition is infused in such an amount as to maintain a mean arterial pressure of about 60 mmHg. The composition may be infused by a pump at a rate of about 1.7 ml/hour decreasing dose-dependent to about 0.4 ml/hour after 24 hours.